FDA Approves Camzyos (Mavacamten) for Obstructive Hypertrophic Cardiomyopathy by Madaline Spencer| Published on: Oct 6, 2026

https://checkrare.com/fda-approves-camzyos-mavacamten-for-obstructive-hypertrophic-cardiomyopathy/ FDA Approves Camzyos (Mavacamten) for Obstructive Hypertrophic Cardiomyopathy by Madaline Spencer| Published on: Oct 6, 2026 The US Food and Drug Administration (FDA) has approved Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in patients weighing 30 kg (66 lbs) or more.